Kyntra Bio (KYNB) Common Equity (2014 - 2026)
Kyntra Bio (KYNB) posted Common Equity of -$43.8 million for Q1 2026, down 157.59% sequentially from -$17.0 million in Q4 2025, and up 77.7% YoY from -$24.7 million in Q1 2025.
Kyntra Bio (KYNB) Common Equity (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Common Equity for 13 years, with the latest figure at -$43.8 million in Q1 2026.
- Quarterly Common Equity rose 77.7% year-over-year to -$43.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.8 million (up 77.7% YoY) and the FY2025 annual result came in at -$17.0 million, up 92.46% from the prior year.
- Common Equity eased to -$43.8 million in Q1 2026 per KYNB's latest filing, from -$17.0 million in the prior quarter.
- Over five years, Common Equity peaked at $178.0 million in Q1 2022 and troughed at -$243.7 million in Q3 2024.
- A 5-year average of -$88.1 million and a median of -$81.8 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2025: Common Equity plunged 851.96% in 2023, then surged 98.36% in 2025.
- Over 5 years, Common Equity stood at -$21.4 million in 2022, then slumped by 851.96% to -$204.2 million in 2023, then fell by 10.5% to -$225.6 million in 2024, then jumped by 92.46% to -$17.0 million in 2025, then sank by 157.59% to -$43.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$43.8 million, -$17.0 million, and -$4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 9.79 Bn |
| 10 | Kyntra Bio | 29.96 Mn | 29.96 Mn | 1.47 Mn | -30.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.14 Mn |
| Mar 31, 2026 | -43.80 Mn |
| Dec 31, 2025 | -17.01 Mn |
| Sep 30, 2025 | -4.00 Mn |
| Jun 30, 2025 | -202.51 Mn |
| Mar 31, 2025 | -196.41 Mn |
| Dec 31, 2024 | -225.60 Mn |
| Sep 30, 2024 | -243.67 Mn |
| Jun 30, 2024 | -211.85 Mn |
| Mar 31, 2024 | -207.64 Mn |
| Dec 31, 2023 | -204.17 Mn |
| Sep 30, 2023 | -136.68 Mn |
| Jun 30, 2023 | -81.79 Mn |
| Mar 31, 2023 | -28.89 Mn |
| Dec 31, 2022 | -21.45 Mn |
| Sep 30, 2022 | 26.31 Mn |
| Jun 30, 2022 | 123.75 Mn |
| Mar 31, 2022 | 178.02 Mn |
| Dec 31, 2021 | 229.11 Mn |
| Sep 30, 2021 | 325.79 Mn |